Related Experiment Videos
Adalimumab (HUMIRA): a review
1Columbia University Medical School, St.-Lukes Roosevelt Hospital Center, 1090 Amsterdam Ave., Suite 11C, New York, NY 10025, USA. NSS32@columbia.edu
Journal of Drugs in Dermatology : JDD
|July 30, 2003
Summary
Adalimumab is a new biologic therapy targeting tumor necrosis factor-alpha, approved for rheumatoid arthritis and being studied for psoriasis. This review covers its action, trials, and clinical use.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Adalimumab is a fully human monoclonal antibody.
- It targets tumor necrosis factor-alpha (TNF-alpha).
- TNF-alpha plays a key role in inflammatory processes.
Purpose of the Study:
- To review the mechanisms of action of adalimumab.
- To summarize clinical trial results for adalimumab.
- To discuss the clinical application and implications of adalimumab.
Main Methods:
- Review of existing literature and clinical trial data.
- Analysis of adalimumab's pharmacodynamics and pharmacokinetics.
- Synthesis of information on efficacy and safety.
Main Results:
- Adalimumab demonstrates significant efficacy in treating rheumatoid arthritis.
- Ongoing trials show promise for psoriasis and psoriatic arthritis.
- The drug's mechanism involves neutralizing TNF-alpha activity.
Conclusions:
- Adalimumab represents a significant advancement in biologic therapy for inflammatory conditions.
- Its targeted approach offers a valuable treatment option.
- Further research is ongoing to expand its therapeutic applications.